Steven A Wrighton

Potentially increasing the metabolic stability of drug candidates via computational site of metabolism prediction by CYP2C9: The utility of incorporating protein flexibility via an ensemble of structures.

Markus A Lill, Matthew L. Danielson, Matthew L Danielson, 2011, European journal of medicinal chemistry.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

B. Ring, S. Wrighton, S. Hall, 2002, Drug metabolism and disposition: the biological fate of chemicals.

The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective

Amy Roe, Volker Fischer, John Kao, 2003, Journal of clinical pharmacology.

Prediction of CYP3A-Mediated Drug-Drug Interactions Using Human Hepatocytes Suspended in Human Plasma

Jialin Mao, S. Wrighton, M. Mohutsky, 2011, Drug Metabolism and Disposition.

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Kimberley Jackson, Ivelina Gueorguieva, Jenny Y Chien, 2010, British journal of clinical pharmacology.

The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity.

S. Wrighton, J. Gorski, S. Hall, 2002, British journal of clinical pharmacology.

STOCHASTIC PREDICTION OF CYP3A-MEDIATED INHIBITION OF MIDAZOLAM CLEARANCE BY KETOCONAZOLE

Jenny Y Chien, S. Wrighton, J. Chien, 2006, Drug Metabolism and Disposition.

Identification of the human cytochromes P450 responsible for atomoxetine metabolism.

J. Gillespie, B. Ring, S. Wrighton, 2002, Drug metabolism and disposition: the biological fate of chemicals.

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Amy Roe, R Scott Obach, Volker Fischer, 2003, Drug metabolism and disposition: the biological fate of chemicals.